Development of a panel of 15 human ovarian cancer xenografts for drug screening and determination of the role of the glutathione detoxification system

Gynecologic Oncology

Volumn 76, Issue 3, 2000, Pages 362-368

  Kolfschoten, Geertruida M ^a   Pinedo, Herbert M ^a   Scheffer, Peter G ^a   Schlüper, Hennie M M ^a   Erkelens, Caroline A M ^a   Boven, Epie ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Drug resistance; Glutathione; Glutathione dependent enzymes; Ovarian cancer xenografts

Indexed keywords

ALTRETAMINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; GLUTATHIONE PEROXIDASE; METHOTREXATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DETOXIFICATION; DRUG DETERMINATION; DRUG SCREENING; DRUG SENSITIVITY; FEMALE; HISTOLOGY; MOUSE; NONHUMAN; NUDE MOUSE; OVARY CANCER; PRIORITY JOURNAL; TUMOR GROWTH; XENOGRAFT;

EID: 0034056485     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5689     Document Type: Article

References (24)

1. Neijt J P, Ten Bokkel Huinink W W, Van der Burg M EL, Van Oosterom A T, Willemse P HB, Vermorken J B, Van Lindert P HB, Heintz A PM, Aartsen E, Van Lent M, Trimbos J B, De Meijer A J. Long-term survival in ovarian cancer. Eur J Cancer. 27:1991;1367-1372.
2. McGuire W P, Hoskins W J, Brady M F, Kucera P R, Partridge E E, Look K Y, Clarke-Pearson D L, Davidson M. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 334:1996;1-6.
3. Johnson S W, Ozols R F, Hamilton T C. Mechanisms in drug resistance in ovarian cancer. Cancer. 71:1993;644-649.
4. Schröder C P, Godwin A K, O'Dwyer P J, Tew K D, Hamilton T C, Ozols R F. Glutathione and drug resistance. Cancer Invest. 14:1996;158-168.
5. Black S M, Wolf C R. The role of glutathione-dependent enzymes in drug resistance. Pharmacol Ther. 51:1991;139-154.
6. Molthoff C FM, Calame J J, Pinedo H M, Boven E. Human ovarian cancer xenografts in nude mice: characterization and analysis of antigen expression. Int J Cancer. 47:1991;72-79.
7. Boven E. Conventional agents in human ovarian cancer xenografts. Winograd B, Peckham M J, Pinedo H M. Human Tumor Xenografts in Anticancer Drug Development. 1988;33-35 Springer-Verlag, Berlin.
8. Neuschwander-Tetri B A, Roll F J. Glutathione measurement by high-performance liquid chromotography separation and fluorometric detection of the glutathione-orthophthalaldehyde adduct. Anal Biochem. 179:1989;236-241.
9. Habig W H, Pabst M J, Jakoby W B. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem. 249:1974;7130-7139.
10. Lawrence R A, Burk R F. Glutathione peroxidase activity in selenium-deficient rat liver. Biochem Biophys Res Commun. 71:1976;952-958.
11. Carlberg I, Mannervik B. Glutathione reductase. Methods Enzymol. 113:1985;484-490.
12. Neijt J P, Ten Bokkel Huinink W W, Van der Burg M EL, Van Oosterom A T, Vriesendorp R, Pinedo H M. Current status of systemic chemotherapy in the treatment of advanced ovarian cancer with emphasis on CHAP-5. Radiother Oncol. 2:1984;19-29.
13. Manetta A, Tewari K, Podczaski E S. Hexamethylmelamine as a single second-line agent in ovarian cancer: follow-up report and review of the literature. Gynecol Oncol. 66:1997;20-26.
14. Boven E, Nauta M M, Schlüper H MM, Erkelens C AM, Pinedo H M. Superior efficacy of trimelamol to hexamethylmelamine in human ovarian cancer xenografts. Cancer Chemother Pharmacol. 18:1986;124-128.
15. Boven E, Venema-Gaberscek E, Erkelens C AM, Bissery M C, Pinedo H M. Antitumor activity of taxotere (RP 56976, NSC 628503), a new Taxol analog, in experimental ovarian cancer. Ann Oncol. 4:1993;321-324.
16. Mistry P, Kelland L R, Abel G, Sidhar S, Harrap K R. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines. Br J Cancer. 64:1991;215-220.
17. Godwin A K, Meister A, O'Dwyer P J, Huang C S, Hamilton T C, Anderson M E. High resistance to cisplatin in human ovarian cancer cell lines is associated with marked increase of glutathione synthesis. Proc Natl Acad Sci USA. 89:1992;3070-3074.
18. Ghazal-Aswad S, Hogarth L, Hall A G, George M, Sinha D P, Lind M, Calvert A H, Sunter J P, Newell D R. The relationship between tumor glutathione concentration, glutathione S-transferase isoenzyme expression and response to single agent carboplatin in epithelial ovarian cancer patients. Br J Cancer. 74:1996;468-473.
19. Van der Zee A GJ, Van Ommen B, Meijer C, Hollema H, Van Bladeren P J, De Vries E GE. Glutathione S-transferase activity and isoenzyme composition in benign ovarian tumors, untreated malignant ovarian tumors, and malignant ovarian tumors after platinum/cyclophosphamide chemotherapy. Int J Cancer. 66:1992;930-936.
20. Britten R A, Green J A, Warenius H M. Cellular glutathione (GSH) and glutathione S-transferase (GST) activity in human ovarian tumor biopsies following exposure to alkylating agents. Int J Radiat Oncol Biol Phys. 24:1992;527-531.
21. Cheng X, Kigawa J, Minagawa Y, Kanamori Y, Itamochi H, Okada M, Terakawa N. Glutathione S-transferase-π expression and glutathione concentration in ovarian carcinoma before and after chemotherapy. Cancer. 79:1997;521-527.
22. Murphy D, McGown A T, Hall A, Cattan A, Crowther D, Fox B W. Glutathione S-transferase activity and isoenzyme distribution in ovarian tumor biopsies taken before or after cytotoxic chemotherapy. Br J Cancer. 66:1992;937-942.
23. Lee F YF, Siemann D W. Isolation by flow cytometry of a human ovarian tumor cell subpopulation exhibiting a high glutathione content phenotype and increased resistance to adriamycin. Int J Radiat Oncol Biol Phys. 16:1989;1315-1319.
24. Lee F YF, Siemann D W, Sutherland R M. Changes in cellular glutathione content during Adriamycin treatment in human ovarian cancer - a possible indicator of chemosensitivity. Br J Cancer. 60:1989;291-298.